Introduction
============

L-carnitine is a natural constituent of higher organisms, including animal cells \[[@B1]\]. It is mainly obtained from dietary sources, particularly red meat and dairy products. Previous reports have revealed that long-term tube feeding with commercial products containing low or no carnitine can contribute to altered mental states caused by hyperammonemia \[[@B2]\]. Lack of carnitine causes the accumulation of unoxidized fatty acids, which inhibit the urea cycle, resulting in hyperammonemia. Adults with chronic illnesses such as advanced cancer and chronic renal failure with hemodialysis are prone to carnitine deficiency because of decreased intake, increased utilization, or increased elimination of carnitine. Intravenous L-carnitine treatment improved patient-assessed fatigue in patients undergoing hemodialysis \[[@B3]\]. However, L-carnitine supplementation to treat carnitine deficiency did not improve fatigue in patients with invasive malignancies and good performance status \[[@B4]\].

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that results in severe muscle atrophy. There is no effective treatment, and patients with ALS usually require mechanical ventilation and long-term tube feeding. We describe the case of a patient with ALS who required long-term tube feeding and whose mental state deteriorated because of carnitine deficiency, despite normal ammonium levels.

Case presentation
=================

A 72-year-old Japanese man had a 12-year history of ALS. He was bedridden and had been on mechanical ventilation and percutaneous endoscopic gastrostomy (PEG) tube feeding at home for the previous 10 years. He was fed 1000mL (1000kcal) of a commercial product (Ensure liquid®; Abbott Japan, Tokyo, Japan) containing \<1nmol/mL of carnitine per day. He was also sometimes given homemade products such as miso soup and coffee with milk, all via the PEG tube. Over one year, his ability to communicate using facial expressions gradually deteriorated. He was still able to flex his left toe to control the communication device, but his energy appeared to diminish when attempting to focus on communication. He did not have muscle cramps, and his diabetes mellitus was well controlled with 25mg of alogliptin without renal insufficiency. His medical history included a colonic polyp, which was resected via endoscopy four years previously, and pneumothorax, which was treated conservatively one year previously. He had no history of rhabdomyolysis.

Laboratory evaluations performed to determine the cause of his altered mental state showed that his electrolytes, hematological parameters, including HbA1c, and liver and renal function parameters were within normal ranges (Table [1](#T1){ref-type="table"}). However, his serum total carnitine was abnormally low, at 26.7μmol/L (normal range, 45 to 91μmol/L), as were his free carnitine (20.6μmol/L; normal range, 36 to 74μmol/L) and acylcarnitine ester (6.1μmol/L; normal range, 6 to 23μmol/L) levels. However, his ammonium level was normal (48μg/dL; normal range, 12 to 68μg/dL).

###### 

Laboratory tests (29 June 2012)

  **Parameter**                   **Laboratory result**   **Parameter**                          **Laboratory result**
  ------------------------------- ----------------------- -------------------------------------- -----------------------
  White blood cells               5800/μL                 Total cholesterol                      157mg/dL
  Red blood cells                 419 × 10^4^/μL          Triglyceride                           165mg/dL
  Hemoglobin                      12.3g/dL                High density lipoprotein cholesterol   33mg/dL
  Platelets                       20.4 × 10^4^/μL         Low density lipoprotein cholesterol    100mg/dL
  Total protein                   7.2g/dL                 Sodium                                 142mEq/L
  Creatinine kinase               22U/L                   Potassium                              3.7mEq/L
  Total bilirubin                 0.3mg/dL                Chloride                               106mEq/L
  Aspartate transaminase          17U/L                   Blood urea nitrogen                    21.9mg/dL
  Alanine transaminase            10U/L                   Creatinine                             0.14mg/dL
  Lactate dehydrogenase           145U/L                  Uric acid                              5.8mg/dL
  Gamma-glutamyl transpeptidase   26U/L                   Blood glucose                          192mg/dL
  Cholinesterase                  237U/L                  HbA1c^a^                               5.8%
  Amylase                         101U/L                                                          

^a^National Glycohemoglobin Standardization Program.

Within two weeks of starting carnitine supplementation (600mg twice daily via the PEG tube), our patient's mental state improved to the level noted the previous year. His serum total carnitine recovered to 172.3μmol/L (normal range, 45 to 91μmol/L) one year after starting carnitine supplementation. His free carnitine (140.6μmol/L; normal range, 36 to 74μmol/L) and acylcarnitine ester (31.7μmol/L; normal range, 6 to 23μmol/L) levels had also recovered at this time. Our patient's mental state has been maintained since starting carnitine supplementation.

Discussion
==========

L-carnitine is found in a variety of food sources but is highly abundant in animal products. Ensure liquid® is made from soybeans and casein, which are low in carnitine \[[@B5]\]. Our patient was given coffee with milk, but his total dietary carnitine intake appeared to be low. In healthy individuals, low carnitine intake does not always lead to carnitine deficiency because of abundant muscle stores, efficient reabsorption in the kidneys, and endogenous synthesis in the liver from lysine and methionine, which are present in sufficient amounts in Ensure liquid®. Normally, more than 95% of the body's total carnitine content would be stored in skeletal muscle \[[@B6],[@B7]\]. However, in patients with ALS, severe muscle atrophy could reduce the carnitine stores, thus contributing to secondary carnitine deficiency caused by long-term enteral feeding with low-carnitine products.

Decreased plasma carnitine levels are an early marker of impending secondary carnitine deficiency in tissues. Low carnitine levels result in the accumulation of unoxidized fatty acids, causing hyperammonemia through inhibition of the urea cycle. Indeed, carnitine deficiency has been reported in patients with hyperammonemia \[[@B8],[@B9]\]. However, hyperammonemia was not seen in our patient. Anticonvulsants such as phenytoin and valproate \[[@B5],[@B8]\] and long-term administration of pivalate-containing antibiotics \[[@B10]\] have been reported to lower carnitine levels. Our patient did not take any drugs known to reduce carnitine levels.

Measuring plasma carnitine levels may help clinicians to differentiate between the progression of ALS and carnitine deficiency in patients with gradual impairments in communication, especially in patients receiving long-term tube feeding with commercial products. In transgenic mouse models with similar phenotypes to ALS in humans, muscle apoptosis was prevented by L-carnitine supplementation \[[@B11]\]. However, further research on L-carnitine supplementation is needed to confirm its role in preventing disease progression in patients with ALS.

Conclusions
===========

Patients with ALS experience progressive muscle atrophy; therefore, it is inevitable that they will lose the ability to communicate over time. Many Japanese patients with ALS requiring PEG feeding are given nutritional products approved by the Ministry of Health, Labor and Welfare that are made from soybeans and casein, but frequently contain low levels of L-carnitine. To avoid gradual impairments in communication caused by secondary carnitine deficiency, clinicians should be aware of and regularly measure their patients' carnitine levels, regardless of their serum ammonia levels. If carnitine supplementation is necessary, it should be administered in the form of L-carnitine tablets or other products containing carnitine.
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